BiotechTube

AXN-2510

Phase 1Active
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumor, Adult

Conditions

Solid Tumor, Adult

Trial Timeline

Sep 15, 2025 → May 15, 2027

NCT ID
NCT07159828

About AXN-2510

AXN-2510 is a phase 1 stage product being developed by Instil Bio for Solid Tumor, Adult. The current trial status is active. This product is registered under clinical trial identifier NCT07159828. Target conditions include Solid Tumor, Adult.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07159828Phase 1Active

Competing Products

20 competing products in Solid Tumor, Adult

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
30
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
25
BT1718Bicycle TherapeuticsPhase 1/2
33
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25
agenT-797 + Approved ICIsMiNK TherapeuticsPhase 1
25
LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367Eli LillyPhase 1
33
BBP-398LianBioPhase 1
25

Other Products from Instil Bio

ITIL-168Phase 2
44
ITIL-306Phase 1
25
ITIL-168Phase 1
25